Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Date:2/21/2012

as global macroeconomic headwinds.  Thanks to the dedication and hard work of our employees around the world, we delivered a very strong finish to a very strong year.  On the heels of the momentum that we've built in 2011, we enter what we believe will be one of the best years in Mylan's history, confident, focused and as committed as ever to delivering on our business strategy and financial targets."  

John Sheehan, Mylan's Chief Financial Officer added:  "In addition to the operational excellence demonstrated, and robust cash flows realized, we exceeded our stated objective with respect to de-leveraging our balance sheet and achieved a leverage ratio of approximately 2.9:1 at the end of 2011."  

Later today, Mylan will host an investor meeting in New York City.   Robert J. Coury, Mylan's Executive Chairman; Heather Bresch, Chief Executive Officer; Rajiv Malik, President; Hal Korman, Chief Operating Officer; John Sheehan, Chief Financial Officer; and John Thievon, President of Mylan Specialty, will review the company's 2011 financial results, present the company's financial guidance for 2012 and provide an overview of the company's strategic vision and growth strategy for 2013 and beyond.

Financial Results SummaryThree Months Ended December 31, 2011Total third party revenues for the three months ended December 31, 2011, increased $96.7 million, or 6.7%, to $1.53 billion from $1.43 billion in the comparable prior year period. The effect of foreign currency translation had an unfavorable impact of approximately 1% on total third party revenues primarily reflecting a stronger U.S. Dollar in comparison to the currencies of the other major markets in which Mylan operates. Translating third party revenues for the current quarter at prior year comparative period exchange rates would have resulted in year-over-year growth excluding foreign currency of approximately $115 million, or 8%.  

A tabular summary of
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
10. Mylan Launches First Generic Version of Teveten® Tablets
11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Array BioPharma Inc. (NASDAQ: ARRY ... and full year of its fiscal year ended ... Executive Officer of Array, noted, "Binimetinib and encorafenib, two ... track for regulatory submissions in 2016. Additional data ... BRAF-mutant colorectal cancer further validate the value of ...
(Date:8/3/2015)... Aug. 3, 2015  Charleston Laboratories, Inc., an ... second clinical development program with a Phase 1 ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  ... a treatment for migraine headache pain and migraine-induced ... patients with migraine headaches also suffer from nausea ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, ... met its primary and secondary endpoints in a phase ... constipation (OIC) in adult patients with chronic non-cancer pain. ... antagonist (PAMORA). This is the third Phase III trial ... endpoints. Study results showed that a 0.2 ...
Breaking Medicine Technology:Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 10Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 11Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2015 12Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
... Biosafety , , , ... June 29 Remember chemistry sets, ham radio, amateur astronomy, and early ... around the world belong to the Do-It-Yourself Biology (DIYbio) community, working on everything ... treatments for diseases. , , , ...
... Ireland , June 28 Warner Chilcott plc ... IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification ... Application (ANDA) by Par for a generic version of the Company,s ASACOL ... , , ...
Cached Medicine Technology:Responsible Science for Do-It-Yourself Biologists 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 2Warner Chilcott Announces Receipt of Paragraph IV Certification Notice 3
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Did you know ... Orange County looking for exceptional and affordable home care options which A-1 Home Care ... just a few of the credentials A-1 Home Care Agency is known ...
(Date:8/2/2015)... (PRWEB) , ... August 03, 2015 , ... A new ... of some childhood cancers. The study is led by Kenneth G. Lucas, M.D. ... University of Louisville in collaboration with colleagues at Kosair Children’s Hospital and ...
(Date:8/2/2015)... ... , ... Molecular biologists in New South Wales say a protein linked to ... posted an article on the new research. Click here to read it now. ... in tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation ...
(Date:8/1/2015)... ... August 01, 2015 , ... ... are in “a trending profession” that comprises a growing percentage of U.S. physicians, ... most. , That was one part of the message delivered by John W. ...
Breaking Medicine News(10 mins):Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5
... de Toulouse-Lautrec suffered, is a genetic disease characterized by ... into how joints are destroyed by arthritis. It is ... K which hampers osteoclasts (the cells that break down ... bone resorption and dense, brittle bones. , Cathepsin ...
... Patients Received Assistance with Drug Co-Pays, HOUSTON, Nov. ... a national oral oncology specialty pharmacy, has,exceeded the $10 ... co-pays since the launch of Care Advantage in August ... Advantage to be able to,increase patient access to oral ...
... 4 Mylan Inc. (NYSE: MYL ),today ... approval from the U.S. Food and Drug Administration ... Levetiracetam Tablets, 250 mg,500 mg and 750 mg. ... Keppra(R)., Robert J. Coury, Mylan,s Vice Chairman ...
... blood pressure experienced during pregnancy could be a woman,s ... heart disease the number one killer of Canadian ... Gynecology, Graeme Smith. , Called pre-eclampsia, this type ... of all pregnancies. , But because most practicing ...
... , , TUESDAY, Nov. 4 (HealthDay News) -- Children who live ... undernourished, a new study finds. , The same is true ... impact the most, said study author Dr. Michael Weitzman, chairman ... "We know that there are long-term consequences of food insecurity ...
... Secretary and other members of bipartisan,group of Capitol ... energy, transportation, trade, labor and employment,and tax policy, ... and grueling,Presidential campaign, one thing is certain: change ... with or regulated by the federal government,will face ...
Cached Medicine News:Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately 2Health News:Pregnancy disorder signals need to screen for heart disease 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 2Health News:Venable's 'Election Watch Group' Assesses Presidential Election's Impact on Multiple Industries 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: